ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The products are primarily used at emergency departments in hospitals for risk stratification of acute medical patients to improve clinical decisions on discharge and hospitalization.
ViroGates’ suPARnostic® product range measures the protein, suPAR (soluble urokinase Plasminogen Activator Receptor). The protein is naturally occurring in human blood and reflects the immune system’s activation level. A patient’s suPAR level predicts negative outcomes such as short-term mortality across acute and chronic diseases. The suPARnostic® tests are easily integrated into existing hospital workflows and instruments, and the results are available in 10-20 minutes.
The company was founded in 2000 based on the discovery that suPAR was predictive of the outcome in HIV infections and subsequently in many other disease areas. Headquartered in Birkerød, Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.
* Other includes analysis services, freight and handling